Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ICCC
#3453
Immucell Corp
6.4
0
+0.79%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.79%
Monthly Change
+0.63%
6 month change
+4.40%
Year Change
+21.67%
Previous Close
6.3
5
Open
6.4
0
Bid
Ask
Low
6.4
0
High
6.4
0
Volume
3
Markets
US Stock Market
Healthcare
ICCC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
ImmuCell directors to step down at 2026 annual meeting, board changes expected
ImmuCell announces new executive employment agreements and option grants
Niche Focus & Regulation Shape the Future of Healthcare Firms
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript
Earnings call transcript: ImmuCell Q4 2025 sees positive stock movement
ImmuCell reports Q4 sales of $7.6 million, shifts focus to First Defense
ImmuCell Puts Re-Tain On Pause After FDA Letter - ImmuCell (NASDAQ:ICCC)
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio
ImmuCell shifts focus to First Defense after FDA setback for Re-Tain
Top Stock Reports for AbbVie, Coca-Cola & Chevron
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength